➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKesson
McKinsey
Harvard Business School
Merck

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,763,954

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,763,954
Title:Therapeutical uses of eslicarbazepine
Abstract: New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions.
Inventor(s): Soares Da Silva; Patricio Manuel Vieira Ara (Porto, PT)
Assignee: BIAL--PORTELA & CA, S.A. (S. Mamede do Coronado, PT)
Application Number:14/134,843
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,763,954
Patent Claims: 1. A method for treating an intractable epilepsy condition comprising administering to a subject in need thereof a therapeutically effective amount of eslicarbazepine or eslicarbazepine acetate wherein the subject has previously been treated with oxcarbazepine.

2. The method according to claim 1, wherein the subject is under 2 years of age.

3. The method according to claim 1, wherein the eslicarbazepine or eslicarbazepine acetate is administered in the absence of a P-glycoprotein inhibitor or a Multiple Resistant Protein inhibitor.

4. The method according to claim 1, wherein the intractable state of the condition is due to overexpression of P-glycoprotein and/or Multiple Resistant Protein.

5. The method according to claim 1, wherein the intractable condition is a pharmacoresistant condition.

6. The method according to claim 1, wherein the intractable condition is a refractory condition.

7. The method according to claim 1, wherein the subject suffers from a relapse after treatment with at least one pharmaceutical composition.

8. The method according to claim 1, wherein the subject is a partial epilepsy refractory patient.

9. The method according to claim 1, wherein the subject has not become seizure-free despite treatment with two or more anti-epileptic drugs.

10. The method according to claim 9, wherein the subject has not become seizure-free despite treatment with two or more anti-epileptic drugs administered at their maximal tolerated dose.

11. The method according to claim 1, wherein the subject has become increasingly less responsive to medication and suffers from an increasing number of seizures.

12. The method according to claim 1, wherein the subject has at least 4 seizures per week despite treatment with at least one anti-epileptic drug.

13. The method according to claim 1, wherein the subject is a patient with drug-resistant epilepsy who has tried at least 3-4 other anti-epileptic drugs.

14. The method according to claim 6, wherein the refractory state of the condition is due to over-expression of P-glycoprotein and/or Multiple Resistant Proteins.

15. The method according to claim 1, wherein the medicament that is a substrate for P-glycoprotein or Multiple Resistant Proteins is oxcarbazepine.

16. The method according to claim 1, wherein the subject is administered with a therapeutically effective amount of eslicarbazepine acetate.

17. The method according to claim 1, wherein the subject is administered with a therapeutically effective amount of eslicarbazepine.

18. The method according to claim 1, wherein the epilepsy is temporal lobe epilepsy.

19. The method according to claim 1, wherein the therapeutically effective amount of eslicarbazepine or eslicarbazepine acetate is administered as adjunctive therapy to a subject being treated with at least one other anti-epileptic drug.

20. The method according to claim 1, wherein the subject has previously been treated with a pharmaceutical composition comprising at least one inhibitor of P-glycoprotein or Multiple Resistant Protein.

21. A method for treating an intractable epilepsy condition comprising administering to a subject in need thereof a therapeutically effective amount of eslicarbazepine or eslicarbazepine acetate wherein the subject has previously been treated with oxcarbazepine, and wherein the eslicarbazepine or eslicarbazepine acetate is administered as a monotherapy for treating said condition.

22. The method according to claim 21, wherein the eslicarbazepine or eslicarbazepine acetate is administered in the absence of a P-glycoprotein inhibitor or a Multiple Resistant Protein inhibitor.

23. The method according to claim 21, wherein the intractable state of the condition is due to overexpression of P-glycoprotein and/or Multiple Resistant Protein.

24. The method according to claim 21, wherein the intractable condition is a pharmacoresistant condition.

25. The method according to claim 21, wherein the intractable condition is a refractory condition.

26. The method according to claim 21, further comprising diagnosing the patient at having an intractable epilepsy condition.

27. The method according to claim 21, wherein the subject is administered with a therapeutically effective amount of eslicarbazepine acetate.

28. The method according to claim 21, wherein the subject is administered with a therapeutically effective amount of eslicarbazepine.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Moodys
McKesson
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.